Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetilar Gold is a dietary supplement containing **cetylated fatty acids (CFA)**, specifically a mixture of **cetylated myristic acid and cetylated oleic acid**. It is presented as oral sachets (20 x 10mL per pack) and is intended to support musculoskeletal health, with a purported benefit in improving joint function and reducing musculoskeletal pain[5][3][1][2]. The **mechanism of action** involves CFAs, plant-derived molecules that have been investigated for their anti-inflammatory and lubricating properties on joints and soft tissues, supporting motility and recovery. Cetilar Gold is designed for oral administration, distinct from topically administered Cetilar products. It is certified as gluten- and lactose-free and is marketed as suitable for athletes, free from substances considered to be doping agents[2][5][3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cetilar gold.